Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01911507 · ClinicalTrials.gov registry record · Phase 1
INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer
A Phase 1 study, sponsored by University of California, Davis.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT01911507 is a Phase 1 study that has completed, run by University of California, Davis. The registered enrollment target is 35 participants.
The verdict
NCT01911507, a Phase 1 study, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of c-Met inhibitor INCB028060 and erlotinib hydrochloride when given together in treating patients with previously treated non-small cell lung cancer. C-Met inhibitor INCB028060 and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG erlotinib hydrochloride
- DRUG INC280
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2013-08-27 |
| Est. Completion | 2020-08-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01911507
The ClinicalTrials.gov registry entry for NCT01911507 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which erlotinib hydrochloride is the first listed.
NCT01911507 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01911507 about?
NCT01911507 is a clinical study titled "INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer". This phase I trial studies the side effects and best dose of c-Met inhibitor INCB028060 and erlotinib hydrochloride when given together in treating patients with previously treated non-small cell lung cancer. C-Met inhibitor INCB028060 and erlotinib hydrochloride may stop the growth of tumor cells b...
What is the current status of trial NCT01911507?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2013-08-27. Estimated completion is 2020-08-26.
What interventions are being tested in trial NCT01911507?
The interventions under investigation include: erlotinib hydrochloride (DRUG), INC280 (DRUG).
Who is sponsoring clinical trial NCT01911507?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.